share_log

Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $34 Price Target

Benzinga ·  Nov 7, 2023 06:55

Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $34 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment